Open AccessBiological drugs prescription issues in terms of the new coronaviral infection COVID-19 pandemic. Literature review and clinical case
Author(s) -
Л. С. Круглова,
Е. А. Шатохина,
Aleksandra S. Polonskaia
Publication year - 2020
Publication title -
rossijskij žurnal kožnyh i veneričeskih boleznej
Language(s) - English
Resource type - Journals
eISSN - 2412-9097
pISSN - 1560-9588
DOI - 10.17816/dv50896
Subject(s) - medicine , covid-19 , pandemic , medical prescription , virology , betacoronavirus , coronavirus infections , intensive care medicine , coronavirus , epidemiology , pharmacology , pathology , disease , outbreak , infectious disease (medical specialty)
BACKGROUND:The spread of the novel coronaviral infection has set important medical society goals, such as the development of effective treatment and preventive modalities (including biologic agents) for COVID-19. Moreover, during this pandemic, the management of chronically ill patients that require immunosuppressive therapy is also a matter of great concern. Analysis of currently obtained data has concluded that patients treated with biologic agents have no elevated risk for COVID-19. Leading medical societies give an opinion in their clinical guidelines that management with biologic drugs should be continued during the COVID-19 pandemic. The feasibility of initiating treatment with a biologic agent depends on the risk-benefit ratio for the drug, the assessment of possible complications along with the associated risks for a poor outcome because of an underlying disease.
CASE REPORT:We present a case report of a patient with erythrodermic psoriasis and psoriatic arthritis treated with ixekizumab during COVID-19 quarantine.